[Significance of prostaglandins and other XXXX in the physiology and physiopathology of pregnancy].

@entity1 @entity2871 @entity851 @entity6 @entity1421 @entity9610 @entity1003 @entity3009 @entity1468 @entity916 @entity1813
Numerous investigations in animals and @entity1 on the role of @entity1813 in pregnancy yielded the following results. During normal pregnancy, there is an increased production of @entity1813 with a vasodilatory action, @entity1421 ( @entity1421 ) and prostacyclin (PGI2), especially in the uteroplacental and renal regions. This additional production contributes to a reduction in peripheral resistance so that the increase of blood volume which is specific for pregnancy can occur without increase in blood pressure. The fact that @entity1813 participate in this mechanism is shown by administration of @entity3009 synthesis inhibitors, thus producing a rise in blood pressure. In the autoregulation of the vessels, interactions between @entity916 angiotensin and @entity1421 and PGI2 are thought to play an important role also in pregnancy. In support of this concept it has been shown that the pregnancy-specific reduction in vasoconstrictor action of angiotensin, is abolished when @entity3009 synthesis inhibitors are given. It is assumed that @entity1421 /PGI2 production and the @entity916 angiotensin production influence each other physiologically. Another important factor in the control of the haemodynamics and @entity1003 is represented by the prostacyclin- @entity2871 system. In normal pregnancy there should be a production equilibrium between the two antagonistic @entity1813 . In @entity1468 this equilibrium, which is particularly marked in the placenta and region of the foetal vessels, is disturbed with decreasing PGI2. The main symptoms of @entity1468 --increase in blood pressure, coagulation disturbances and diminished placental circulation--can be derived from this. In @entity6 and @entity851 , both of which predispose to @entity1468 , similar changes in @entity9610 production have been observed. Hence, in case of @entity1468 with disturbed eicosanoid production the administration of @entity3009 synthesis inhibitors such as peripherally acting analgesics and corticoids is contraindicated. Approaches to a rational therapy such as administration of @entity2871 synthesis inhibitors, a diet with @entity3009 precursors and infusions of PGI2 appear promising according to preliminary results. Further advances may be expected after the function of @entity1813 of the lipoxygenase paths in @entity1468 has been elucidated.
